Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>De novo</i> grafted coiled-coil peptides as p53/<i>h</i>DM2 inhibitors.

RSC chemical biology·2026
Same author

De Novo Design of Multivalent α/β-Peptides Mimicking Transcription Factors Targeting the CBP KIX Domain.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Discovery of SHANK1-PDZ Peptide-Fragment Inhibitors Using a Dynamic Ligation Screening Strategy.

Biochemistry·2026
Same author

Boltz-ABFE: Free Energy Perturbation without Crystal Structures.

Journal of chemical theory and computation·2026
Same author

Covalent Peptide-Based N-Myc/Aurora-A Inhibitors Bearing Sulfonyl Fluoride Warheads.

Journal of peptide science : an official publication of the European Peptide Society·2026
Same author

Bora bridges Aurora-A activation and substrate recognition of PLK1.

EMBO reports·2026

Related Experiment Video

Updated: Sep 21, 2025

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy
06:38

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy

Published on: February 7, 2019

8.9K

Understanding p300-transcription factor interactions using sequence variation and hybridization.

Fruzsina Hóbor1,2, Zsófia Hegedüs3, Amaurys Avila Ibarra4,5

  • 1Astbury Centre for Structural Molecular Biology, University of Leeds, Woodhouse Lane Leeds LS2 9JT UK a.j.wilson@leeds.ac.uk t.a.edwards@leeds.ac.uk.

RSC Chemical Biology
|June 3, 2022
PubMed
Summary

Hypoxia-inducible factor 1 (HIF-1) is crucial for tumor survival. This study reveals HIF-1α sequence variations are tolerated due to flexible binding interactions, offering new anticancer drug targets.

More Related Videos

DNA Sequence Recognition by DNA Primase Using High-Throughput Primase Profiling
08:04

DNA Sequence Recognition by DNA Primase Using High-Throughput Primase Profiling

Published on: October 8, 2019

8.8K
Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
10:16

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions

Published on: June 28, 2018

32.7K

Related Experiment Videos

Last Updated: Sep 21, 2025

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy
06:38

High Sensitivity Measurement of Transcription Factor-DNA Binding Affinities by Competitive Titration Using Fluorescence Microscopy

Published on: February 7, 2019

8.9K
DNA Sequence Recognition by DNA Primase Using High-Throughput Primase Profiling
08:04

DNA Sequence Recognition by DNA Primase Using High-Throughput Primase Profiling

Published on: October 8, 2019

8.8K
Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions
10:16

Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions

Published on: June 28, 2018

32.7K

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • The hypoxic response is vital for solid tumor growth and survival.
  • Hypoxia-inducible factor 1 (HIF-1) regulates adaptation to low oxygen by controlling over 100 genes.
  • HIF-1 is a promising target for anticancer drug development.

Purpose of the Study:

  • To investigate the sequence determinants governing the binding interaction of HIF-1α.
  • To understand how sequence variations affect HIF-1α binding to its partners.
  • To explore the potential of HIF-1 pathway modulation for cancer therapy.

Main Methods:

  • Protein expression and chemical synthesis of HIF-1α variants.
  • Fluorescence anisotropy and isothermal titration calorimetry to study binding kinetics.
  • Analysis of HIF-1α sequence variants and a HIF-1α-CITED hybrid (CITIF).

Main Results:

  • HIF-1α sequence variations are well-tolerated, with reduced enthalpic and less unfavorable entropic contributions.
  • Binding interactions are primarily controlled by backbone interactions and ligand folding, not just side chains.
  • Sequence variations lead to a more disordered bound interaction, forming a "fuzzy" complex.

Conclusions:

  • HIF-1α exhibits significant sequence tolerance in its binding interactions.
  • The "fuzzy" complex formation explains the adaptability of HIF-1α to sequence variations.
  • Understanding these binding dynamics can inform the design of novel anticancer drugs targeting HIF-1.